Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press13410.17650/1726-9776-2011-7-2-23-28DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряGENETIC RISK MARKERS FOR SUPERFICIAL AND INVASIVE BLADDER CANCERГЕНЕТИЧЕСКИЕ МАРКЕРЫ РИСКА РАЗВИТИЯ ПОВЕРХНОСТНОГО И ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯPavlovV. N.ПавловВ. Н.
Russian Federation
izmailov75@mail.ruIzmailovA. A.ИзмайловА. А.
Russian Federation
izmailov75@mail.ruViktorovaT. V.ВиктороваТ. В.
Russian Federation
izmailov75@mail.ruIzmailovaS. M.ИзмайловаС. М.
Russian Federation
izmailov75@mail.ruAkhmadishinaL. Z.АхмадишинаЛ. З.
Russian Federation
izmailov75@mail.ruGalimzyanovV. V.Z.ГалимзяновВ. З.
Russian Federation
izmailov75@mail.ruZagidullinA. A.ЗагидуллинА. А.
Russian Federation
izmailov75@mail.ruBashkir State Medical University, Ministry of Health and Social Development of Russia, UfaГОУ ВПО Башкирский государственный медицинский университет Минздравсоцразвития России, УфаBashkir State Medical University, Ministry of Health and Social Development of Russia, Ufa Ufa Research Center, Russian Academy of SciencesГОУ ВПО Башкирский государственный медицинский университет Минздравсоцразвития России, Уфа Уфимский научный центр РАНUfa Research Center, Russian Academy of SciencesУфимский научный центр РАН300620117223282807201428072014https://oncourology.abvpress.ru/oncur/article/view/134

To reveal possible associations of the polymorphic variants of the cytochrome P450 and enzymes glutathione-S-transferase genes with the risk for bladder cancer (BC), the authors analyzed the frequency of genotypes and alleles at the polymorphic loci of the CYP1A1 (A2454G), GSTM1 (del), and GSTP1 (A313G) genes in 208 patients diagnosed as having BC (104 patients with invasive BC and 104 with superficial BC) and in 367 patients without identified oncopathology. The *1A*2C (OR = 3.42) and *2C*2С (OR = 6.98) genotypes, *2C (OR = 3.73) allele of the CYP1A1 gene and the GG (OR = 2.53) genotype of the GSTP1 gene were ascertained to be genetic markers for a risk for BC. The presence of the *2C (OR = 1.69) allele of the CYP1A1 gene, the G (OR = 2.40) allele and the AG genotype (OR = 2.40) of the GSTP1 gene was associated with the invasive forms of BC. There were no substantial differences in the distribution of the frequency of genotypes of the GSTM1 gene between the samples of patients and healthy individuals.

С целью выявления возможных ассоциаций полиморфных вариантов генов цитохрома P450 и ферментов глутатион-S-трансферазы с риском развития рака мочевого пузыря (РМП) нами проведен анализ частот встречаемости генотипов и аллелей полиморфных локусов генов CYP1A1 (A2454G), GSTM1 (del), GSTP1 (A313G) у 208 больных с диагнозом РМП (104 пациента с инвазивным и 104 – с поверхностным раком) и у 367 пациентов без выявленной онкопатологии. Установлено, что генетическими маркерами риска развития РМП являются генотипы *1A*2C (ОP 3,42) и *2C*2С (ОР 6,98), аллель *2C (ОР 3,73) гена CYP1A1, генотип GG (ОР 2,53) гена GSTP1. Наличие аллеля *2C (ОР 1,69) гена CYP1A1, аллеля G (ОР 2,40) и генотипа AG (ОР 2,40) гена GSTP1 ассоциировано с инвазивными формами РМП. Существенных различий в распределении частот встречаемости генотипов гена GSTM1 между выборками больных и здоровых не выявлено.

cancerurinary bladderoncomarkerspolymorphismракмочевой пузырьонкомаркерыполиморфизм1. Аполихин О.А., Какорина Е.П., Сивков А.В. и др. Состояние урологической заболеваемости в Российской Федерации по данным официальной статистики. Урология 2008;(3):5–7.Аполихин О.А., Какорина Е.П., Сивков А.В. и др. Состояние урологической заболеваемости в Российской Федерации по данным официальной статистики. Урология 2008;(3):5–7.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 г. (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2010. 256 с.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 г. (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2010. 256 с.3. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2008 г. Под ред. В.И. Чиссова, В.В. Старинского,Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2008 г. Под ред. В.И. Чиссова, В.В. Старинского,Г.В. Петровой. М., 2009. 192 с. 4. Лоран О.Б. Онкоурология сегодня: проблемы и достижения. Мед вестн 2007;13 (398). http://medvestnik.ru/archive/ 2007/13.5. Fleming F., Huang A., Pu Y. Urinary bladder. In: Cancer staging manual. Philadelphia: Lippincot-Raven,1997; p. 241–24.Fleming F., Huang A., Pu Y. Urinary bladder. In: Cancer staging manual. Philadelphia: Lippincot-Raven,1997; p. 241–24.6. Millan-Rodrigez F., Chechile-Toniolo R., Salvador-Bayarri J. et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163(1):73–8.Millan-Rodrigez F., Chechile-Toniolo R., Salvador-Bayarri J. et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163(1):73–8.7. Баранов В.С., Баранова Е.В., Иващенко Т.Э., Асеев М.В. Геном человека и гены «предрасположенности» (введение в предиктивную медицину). СПб.: Интермедика, 2000. 271 с.Баранов В.С., Баранова Е.В., Иващенко Т.Э., Асеев М.В. Геном человека и гены «предрасположенности» (введение в предиктивную медицину). СПб.: Интермедика, 2000. 271 с.8. Кулинский В.И. Обезвреживание ксенобиотиков. Соросовск образоват журн 1999;(1):8–12.Кулинский В.И. Обезвреживание ксенобиотиков. Соросовск образоват журн 1999;(1):8–12.9. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65–76.Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65–76.10. Brockmoller J., Cascorbi I., Kerb R. Combined analysis of inherited polymorphisms in arylamine Nacetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P 450 enzymes as midulatiors of bladder cancer risk. Cancer Res 1996;56:3915–25.Brockmoller J., Cascorbi I., Kerb R. Combined analysis of inherited polymorphisms in arylamine Nacetyltransferase 2, glutathione S-transferase M1 and T1, microsomal epoxide hydrolase, and cytochrome P 450 enzymes as midulatiors of bladder cancer risk. Cancer Res 1996;56:3915–25.11. Buch S., Kotekar A., Kawle D. et al. Polymorphisms at CYP and GST gene loci. Eur J Clin Pharmacol 2001;57:553–5.Buch S., Kotekar A., Kawle D. et al. Polymorphisms at CYP and GST gene loci. Eur J Clin Pharmacol 2001;57:553–5.12. Egan K.M., Cai Q., Shu X.O. et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers prev 2004; 13(2):197–204.Egan K.M., Cai Q., Shu X.O. et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers prev 2004; 13(2):197–204.13. Baranov V.S., Ivaschenko T., Bakay B. et al. Proportion of the GSTM1 0/0 genotipe in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 1996;97:516–20.Baranov V.S., Ivaschenko T., Bakay B. et al. Proportion of the GSTM1 0/0 genotipe in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 1996;97:516–20.14. Krajinovic M., Labuda D., Richer Ch. et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93(5):1496–501.Krajinovic M., Labuda D., Richer Ch. et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93(5):1496–501.15. www.statistica.com StatSoft Inc.-USA. Statistica v.6.0.www.statistica.com StatSoft Inc.-USA. Statistica v.6.0.16. Allard P., Bernard P., Fradet Y. The early Clinical course of primary Ta and T1 bladder cancer. Europ Urol 1998;8(1):692–8.Allard P., Bernard P., Fradet Y. The early Clinical course of primary Ta and T1 bladder cancer. Europ Urol 1998;8(1):692–8.17. Malmstrom P., Busch C., Norlen B.J. Recurrences, progression and survial in bladder cancer. Scand J Urol Nephrol 1987;21(2):185.Malmstrom P., Busch C., Norlen B.J. Recurrences, progression and survial in bladder cancer. Scand J Urol Nephrol 1987;21(2):185.18. Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica 2002;18(2):357–77.Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica 2002;18(2):357–77.19. Miller D.P., Liu G. De Vivo I. et al. Combinations of the variant genotypes of GSTP1, GSTM1 and p53 are assotiated with the lung cancer risk. Cancer Res 2002;62:2819–23.Miller D.P., Liu G. De Vivo I. et al. Combinations of the variant genotypes of GSTP1, GSTM1 and p53 are assotiated with the lung cancer risk. Cancer Res 2002;62:2819–23.20. Nebert D.W. Polymorphisms in drugmetabolizing enzymes: What is their Clinical relevance and Why do they exist? Fm J Hum Genet 1997;60:265–71.Nebert D.W. Polymorphisms in drugmetabolizing enzymes: What is their Clinical relevance and Why do they exist? Fm J Hum Genet 1997;60:265–71.21. Pande M., Amos C.I., Osterwisch D.R. et al. Cancer Epidemiol Biomarkers Prev 2008;17(9):2393–401.Pande M., Amos C.I., Osterwisch D.R. et al. Cancer Epidemiol Biomarkers Prev 2008;17(9):2393–401.22. Grando J.P., Kuasne H., Losi–Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med 2009;9(1):21–8.Grando J.P., Kuasne H., Losi–Guembarovski R. et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med 2009;9(1):21–8.23. Fontana L., Delort L., Joumard L. et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a french cohort. Anticancer Res 2009;29(5):1631–5.Fontana L., Delort L., Joumard L. et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a french cohort. Anticancer Res 2009;29(5):1631–5.24. Steinhoff C., Franke K.H. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000;74(9):521–6.Steinhoff C., Franke K.H. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000;74(9):521–6.25. Yuan J.M., Chan K.K., Coetzee G.A. et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis 2008;29(7):1386–93.Yuan J.M., Chan K.K., Coetzee G.A. et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis 2008;29(7):1386–93.26. Garcia–Closas M., Malats N. et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366(9486):649—59.Garcia–Closas M., Malats N. et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366(9486):649—59.27. Dong L.M., Potter J.D., White E. et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008;299(20):2423–36.Dong L.M., Potter J.D., White E. et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008;299(20):2423–36.28. Hsu L.I., Chiu A.W., Huan S.K. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol 2008;228(2):144–55.Hsu L.I., Chiu A.W., Huan S.K. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol 2008;228(2):144–55.29. Altayli E., Gunes S., Yilmaz A.F. et al. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009;41(2):259–66.Altayli E., Gunes S., Yilmaz A.F. et al. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 2009;41(2):259–66.30. Querhani S., Tebourski F., Slama M.R. et al. The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisia. Ann Hum Biol 2006;33(5–6):529–35.Querhani S., Tebourski F., Slama M.R. et al. The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisia. Ann Hum Biol 2006;33(5–6):529–35.31. Rahman I., Biswas S.K., Kode A. Oxidant and antioxidant balance in the airway diseases. Eur J Pharmacol 2006;533:222–39.Rahman I., Biswas S.K., Kode A. Oxidant and antioxidant balance in the airway diseases. Eur J Pharmacol 2006;533:222–39.32. Mittal R.D., Srivastava D.S., Mandhani A. et al. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev 2005;6(1):6–9.Mittal R.D., Srivastava D.S., Mandhani A. et al. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev 2005;6(1):6–9.33. Kellen E., Hemelt M., Broberg K. et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer: a HuGE–GSEC review. Am J Epidemiol 2007;165(11):1221–30.Kellen E., Hemelt M., Broberg K. et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer: a HuGE–GSEC review. Am J Epidemiol 2007;165(11):1221–30.34. Mo Z., Gao Y., Cao Y. et al. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 2009;69(6):662–88.Mo Z., Gao Y., Cao Y. et al. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 2009;69(6):662–88.